Novartis: positive data in prostate cancer

(CercleFinance.com) - Novartis announces positive initial results from the Phase III VISION study evaluating its 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant, prostate cancer.


This study met both primary endpoints, significantly improving overall survival and radiographic progression-free survival (rPFS) in patients compared to the best standard of care alone.

The safety profile is consistent with data reported from previous studies. The trial results will be presented at an upcoming medical meeting, with regulatory submissions in the US and EU expected in 2021.


Copyright (c) 2021 CercleFinance.com. All rights reserved.